Compare AstraZeneca plc (AZN) vs Expedia Group Inc (EXPE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Expedia Group Inc — how do they compare? AstraZeneca plc trades at $157.73 (market cap $248.14B), while Expedia Group Inc trades at $317.79 (market cap $38.53B). The key difference: AstraZeneca plc is far larger — about 6.4× Expedia Group Inc's market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AZN | EXPE | |
|---|---|---|
Market Cap | $248.14B | $38.53B |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $321.07 |
52-Week Low | $147.06 | $188.51 |
Enterprise Value | $275.41B | $37.09B |
Dividend Yield | 2.01% | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.
The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.
Expedia Group (EXPE) trades at $314.01, up 1.07% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q2 2026 EPS of $5.76 beating estimates by 10.3% and revenue growth accelerating to 14% year-over-year. Recent earnings show continued B2B momentum and AI-driven efficiency improvements, with the company raising full-year revenue guidance to $16.05-16.22 billion. Valuation metrics remain reasonable with P/E of 20.19 and EV/EBITDA of 10.04, while profitability metrics show impressive ROE of 199.12% and net margin of 12.97%.
Expedia presents a favorable investment case with strong earnings momentum, strategic AI integration, and upward guidance revisions. The stock trades near analyst consensus target of $322.95 with 47% buy ratings, though RSI levels suggest potential near-term overbought conditions. Key risks include travel demand sensitivity to economic conditions and competitive pressures in online travel. The combination of fundamental strength and technical momentum supports a constructive outlook for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →
